A 64-year-old woman with metastatic pancreatic cancer achieved exceptional results with NALIRIFOX chemotherapy, experiencing complete disappearance of her pancreatic tumor and dramatic shrinkage of liver tumors, maintaining disease control for over two years. According to Gram Research analysis of this case report, while individual results vary significantly and this represents a single patient’s experience, the outcome suggests NALIRIFOX may offer meaningful benefits for selected pancreatic cancer patients who typically face poor survival prospects.
A 64-year-old woman with advanced pancreatic cancer that had spread to her liver experienced an unusually positive outcome after receiving a new drug combination called NALIRIFOX. According to Gram Research analysis, she completed 20 rounds of treatment over 25 months and saw her tumors shrink dramatically—the pancreatic tumor disappeared entirely, and her liver tumors shrank significantly. While this is a single case report rather than a large study, it suggests NALIRIFOX may offer hope for some pancreatic cancer patients who typically face very poor survival odds. Researchers emphasize this patient’s excellent response highlights the potential benefits of this treatment approach, though more research is needed to understand which patients benefit most.
Key Statistics
A 2026 case report documented a 64-year-old woman with metastatic pancreatic cancer who achieved complete disappearance of her pancreatic tumor and marked regression of liver metastases after eight cycles of NALIRIFOX treatment over approximately 10 months.
The patient treated with NALIRIFOX maintained disease stability for more than two years before progression occurred, representing an unusually extended survival period compared to the typical 8-12 month median survival for metastatic pancreatic cancer.
A single patient receiving NALIRIFOX as first-line therapy completed 20 treatment cycles over 25 months and experienced substantial improvement in CA 19-9 tumor marker levels alongside radiographic tumor response.
The Quick Take
- What they studied: Whether a new cancer drug called NALIRIFOX could help a patient with advanced pancreatic cancer that had spread throughout her body.
- Who participated: One 64-year-old woman with metastatic pancreatic cancer (cancer that started in the pancreas and spread to the liver). She was treated as part of a larger clinical trial called NAPOLI-3.
- Key finding: The patient experienced remarkable improvement: her pancreatic tumor disappeared completely, her liver tumors shrank dramatically, and she remained cancer-free for over two years—an unusually long survival time for this aggressive cancer type.
- What it means for you: While this is just one patient’s story, it suggests NALIRIFOX may be a promising treatment option for some pancreatic cancer patients. However, individual results vary greatly, and more research with larger groups of patients is needed before drawing firm conclusions.
The Research Details
This is a case report, which means researchers documented the medical journey of a single patient in detail. The 64-year-old woman presented with abdominal pain, early fullness when eating, weight loss, and blood tests showing very high levels of a cancer marker called CA 19-9. Imaging scans revealed a tumor in her pancreas head and multiple tumors in her liver, confirmed by biopsy as poorly differentiated pancreatic adenocarcinoma—an aggressive form of cancer.
The patient received NALIRIFOX, a combination of three chemotherapy drugs, as her first-line treatment (the initial treatment choice). She completed 20 treatment cycles over approximately 25 months. After an early delay due to low white blood cell counts (grade 2 neutropenia), she responded well to the therapy.
Researchers tracked her progress through blood tests measuring CA 19-9 levels and imaging scans showing tumor size. They documented how her tumors responded and how long she remained cancer-free.
Case reports are valuable for documenting unusual or promising outcomes that might warrant further investigation. Pancreatic cancer is notoriously aggressive and difficult to treat, with most patients experiencing poor survival outcomes. When a single patient achieves exceptional results, it provides important clinical evidence that certain treatments may benefit selected patients and justifies larger, more rigorous studies.
This is a single case report, which is the lowest level of scientific evidence. It describes one patient’s experience in detail but cannot prove the drug works for everyone or even most patients. The patient may have had favorable characteristics (age, overall health, tumor type) that contributed to her success. To establish whether NALIRIFOX truly benefits pancreatic cancer patients broadly, results from the larger NAPOLI-3 clinical trial (which this patient participated in) are needed. Case reports are best viewed as promising signals that warrant further investigation rather than definitive proof of effectiveness.
What the Results Show
The patient achieved what oncologists call a ‘substantial response’ to NALIRIFOX treatment. After eight treatment cycles (approximately 10 months), imaging scans showed marked improvement: the pancreatic tumor had disappeared completely, and the multiple liver tumors had shrunk dramatically. Her CA 19-9 blood marker, which was markedly elevated at diagnosis, improved substantially with treatment.
Most remarkably, the patient maintained disease stability—meaning her cancer did not progress—for more than two years after completing eight cycles of treatment. She continued receiving additional cycles (completing 20 total) to maintain this control. This extended period of stability is exceptional for metastatic pancreatic cancer, where most patients experience disease progression within months.
The patient experienced one significant side effect: grade 2 neutropenia (low white blood cell count) early in treatment, which caused a temporary delay in her therapy schedule. After managing this side effect, she tolerated the remaining treatment cycles and continued to benefit from the drug combination.
The case demonstrates that NALIRIFOX can be administered over an extended period (25 months in this patient) with manageable side effects in selected patients. The sustained biochemical response (improvement in CA 19-9 levels) correlated with radiographic response (tumor shrinkage on imaging), suggesting the blood marker accurately reflected treatment effectiveness. Disease progression eventually occurred in a dominant liver lesion after cycle 20, indicating that while the treatment provided prolonged benefit, it was not curative in this case.
Historically, metastatic pancreatic cancer carries a median overall survival of 8-12 months with standard chemotherapy. This patient’s survival of over two years with sustained disease control represents an unusually favorable outcome. NALIRIFOX is a newer combination regimen designed to improve upon standard treatments. While individual case reports cannot establish superiority, this case aligns with emerging data suggesting NALIRIFOX may offer benefits for selected pancreatic cancer patients, which is why the larger NAPOLI-3 trial was conducted to test this hypothesis more rigorously.
This is a single case report describing one patient’s experience, so results cannot be generalized to all pancreatic cancer patients. The patient may have had favorable prognostic factors (such as good overall health, younger age for pancreatic cancer, or tumor characteristics) that contributed to her exceptional response. We cannot determine whether her success was due to NALIRIFOX specifically, her individual biology, or a combination of factors. Case reports lack a comparison group, so we cannot compare her outcome to patients receiving other treatments. To establish whether NALIRIFOX truly benefits pancreatic cancer patients broadly, results from the larger NAPOLI-3 randomized controlled trial are essential. This case should be viewed as a promising signal warranting further investigation rather than proof that all patients will experience similar benefits.
The Bottom Line
For pancreatic cancer patients: NALIRIFOX shows promise as a potential first-line treatment option based on emerging clinical data, but treatment decisions should be made in consultation with your oncology team who can assess your individual situation. For healthcare providers: This case supports consideration of NALIRIFOX for eligible metastatic pancreatic cancer patients, particularly those with good performance status. Confidence level: Moderate—based on emerging trial data and individual case reports, not yet definitive evidence.
Patients with newly diagnosed metastatic pancreatic cancer and their families should be aware of NALIRIFOX as a potential treatment option to discuss with their oncologist. Healthcare providers treating pancreatic cancer should consider this emerging evidence when selecting first-line therapies. Researchers studying pancreatic cancer treatment should note this case as supporting evidence for the NAPOLI-3 trial’s investigation of NALIRIFOX. Patients with early-stage pancreatic cancer should not assume these results apply to their situation, as treatment approaches differ significantly.
In this case, substantial tumor shrinkage was evident after eight treatment cycles (approximately 10 months). Disease stability was maintained for over two years. However, individual responses vary considerably. Some patients may respond faster or slower, and some may not respond at all. Realistic expectations should be discussed with your medical team based on your specific situation.
Frequently Asked Questions
What is NALIRIFOX and how does it work for pancreatic cancer?
NALIRIFOX is a combination of three chemotherapy drugs designed to attack pancreatic cancer cells. This case report describes one patient who achieved remarkable tumor shrinkage and extended survival with NALIRIFOX as first-line treatment, though larger studies are needed to confirm effectiveness across patient populations.
How long did the pancreatic cancer patient survive with NALIRIFOX treatment?
This patient maintained disease control for over two years after starting NALIRIFOX, which is substantially longer than the typical 8-12 month survival for metastatic pancreatic cancer. However, individual outcomes vary significantly based on many factors.
What side effects did the patient experience from NALIRIFOX?
The patient experienced grade 2 neutropenia (low white blood cell count) early in treatment, which caused a temporary delay in therapy. After managing this side effect, she tolerated the remaining 20 treatment cycles reasonably well, though individual side effect experiences vary.
Can I expect the same results as this patient if I have pancreatic cancer?
This case report describes one patient’s exceptional outcome, which cannot be generalized to all pancreatic cancer patients. Individual results depend on many factors including tumor characteristics, overall health, and treatment response. Discuss realistic expectations with your oncology team.
Is NALIRIFOX approved by the FDA for pancreatic cancer treatment?
NALIRIFOX is being studied in clinical trials like NAPOLI-3 to establish its effectiveness and safety. This case report documents one patient’s positive response, but approval decisions depend on results from larger, rigorous clinical trials rather than individual case reports.
Want to Apply This Research?
- If receiving NALIRIFOX treatment, track weekly white blood cell counts and CA 19-9 tumor marker levels (if applicable). Record treatment cycle completion dates, any side effects experienced (especially neutropenia or infections), and imaging scan results. This data helps your care team monitor treatment effectiveness and manage side effects.
- Work with your oncology team to establish a treatment schedule and side effect management plan. Set reminders for blood work appointments and imaging scans. Keep a symptom diary noting any changes in energy, appetite, or side effects between cycles. This information helps your doctor adjust treatment as needed.
- Maintain regular follow-up appointments with your oncology team, typically every 2-4 weeks during active treatment. Track CA 19-9 levels and imaging results at intervals your doctor recommends (usually every 2-3 months). Monitor for signs of infection or severe side effects that require immediate medical attention. After treatment completion, continue surveillance imaging and blood work as recommended to detect any recurrence early.
This article describes a single case report of one patient’s experience with NALIRIFOX treatment and should not be interpreted as medical advice or proof that this treatment works for all pancreatic cancer patients. Case reports represent the lowest level of scientific evidence and document individual experiences that may not be generalizable. Treatment decisions for pancreatic cancer should be made in consultation with qualified oncologists who can evaluate your individual medical situation, tumor characteristics, and overall health status. NALIRIFOX is being studied in clinical trials and may not be appropriate or available for all patients. Always discuss potential benefits, risks, and alternatives with your healthcare team before starting any cancer treatment. This information is current as of 2026 and should be supplemented with the most recent clinical trial results and treatment guidelines from organizations like the National Comprehensive Cancer Network (NCCN).
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.